Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Follitropin Alfa→

Follitropin Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
146479-72-3
Molecular formula
Not available
Molecular weight
~30000 g/mol
Drug class
Recombinant human follicle-stimulating hormone (FSH) gonadotropin
Mechanism of action
Binds FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In men, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin (hCG).
Indications / reported uses
  • Controlled ovarian stimulation to induce development of multiple follicles in women undergoing assisted reproductive technologies
  • Induction of ovulation in selected women with anovulation who have not responded to clomiphene citrate
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism, in combination with hCG; use is product- and jurisdiction-specific

Sources: US DailyMed — GONAL-f (follitropin alfa) · EMA EPAR — Gonal-f · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant human follicle-stimulating hormone (FSH) gonadotropin

Mechanism of action

Binds FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In men, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin (hCG).

General use cases

  • Controlled ovarian stimulation to induce development of multiple follicles in women undergoing assisted reproductive technologies
  • Induction of ovulation in selected women with anovulation who have not responded to clomiphene citrate
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism, in combination with hCG; use is product- and jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Follitropin Alfa Environmental Risk Assessment (ERA) (the Follitropin Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.